In consultation: Guidance and quality standards

Skip to filters Skip to results

Showing 1 to 3 of 3

Sort by

Type: GuidanceRemove Type: Guidance filter
Guidance programme: Technology appraisal guidanceRemove Guidance programme: Technology appraisal guidance filter
Guidance programme: Antimicrobial prescribing guidelinesRemove Guidance programme: Antimicrobial prescribing guidelines filter
Guidance programme: Cancer service guidelinesRemove Guidance programme: Cancer service guidelines filter
Guidance programme: Diagnostics guidanceRemove Guidance programme: Diagnostics guidance filter
Guidance programme: Medical technologies guidanceRemove Guidance programme: Medical technologies guidance filter
Guidance programme: Medicines practice guidelinesRemove Guidance programme: Medicines practice guidelines filter
Guidance programme: Public health guidelinesRemove Guidance programme: Public health guidelines filter
Guidance programme: Social care guidelinesRemove Guidance programme: Social care guidelines filter

Guidance and quality standards in consultation
Title	Consultation	Type	Consultation end date
Marstacimab for treating severe haemophilia A or severe haemophilia B in people 12 years and over [ID6342]	Draft guidance	Technology appraisal guidance	6 February 2025
Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment [ID6370]	Draft guidance	Technology appraisal guidance	4 February 2025
Erdafitinib for treating metastatic or unresectable FGFR-altered urothelial cancer [ID1333]	Draft guidance	Technology appraisal guidance	30 January 2025

Results per page

10
25
50
All